




DXY Insight Database

A Leading Global Drug Competitive Intelligence Database with Deep China Insights

Delivering multi-dimensional competitive intelligence across the entire drug lifecycle, from preclinical research through post-market approval, empowering enterprises to make decisions more precisely and work more efficiently.



Core Modules

A Global Drug Competition Intelligence Platform Covering Data from Preclinical ▶ IND ▶ Clinical Trials ▶ NDA


- Global New Drugs Intelligence
- Data Throughout the Entire Life Cycle of Drugs
- Value-Added Services



Add-on Modules

Market Approval Strategy Analysis

Drug Market Access Pathways Analysis and Approval Timelines Prediction



Target Analysis

Target Value Assessment and Analysis



Market Analysis

Marketing Pricing and Market Access Strategy Analysis



Clinical Strategy Analysis

Panoramic Survey of Investigators and Trial Sites



Enterprise Analysis

Enterprise Identifying and Evaluation



Disease Competition

Epidemiology and Unmet Clinical Needs Analysis



01.

Analyze Global and China Pipeline Competition in Targeted Sectors and Identify BD Opportunities

Identify Pipelines

Screen pipelines in your target sector that are still available for out-licensing and conduct a potential assessment.

The Global Pipelines module covers nearly 100,000 drug pipelines from both China and overseas. To identify pipelines in your target sector that are still available for out-licensing, set the Originator filter with Headquarters Location to Mainland China, and set the Deals filter to No. You can then comprehensively assess a pipeline’s potential by reviewing its R&D track ranking, indication strategy, and relevant clinical, deal, and patent data, ultimately identifying high-value pipelines.

Home

Navigation

Global New Drug Pipelines

Insight Data Monitor (IDM)

Search

Advanced Search

Module Introduction

Global New Drug Pipelines

Search

Research progress

Indications and research status

Indications Lastest Progress Date

The highest status and time of the ...

Project Active / Inactive

Market region

Special Review Channel

FIC and Track Ranking

Trial Results

Project Latest Progress Time

R&D Enterprise

R&D Enterprise

Enterprise type

Headquarters Location

My Collections

Recent Search

FIC and Track Ranking

Please choose from below

Query

Global R&D Track Ranking

Global FIC

Top 3 globally

Top 10 globally

Ranking of R&D tracks in mainland China

FIC in Mainland China

Top 3 Mainland China

Top 10 Mainland China

Ranking of Mainland Chinese Enterprises' Original Developed Drugs in the Mainland R&D Track

Chinese mainland enterprise original research FIC

Top 3 original research institutes of mainland Chinese enterprises

Top 10 Original Research Enterprises in Mainland China

Global New Drug Pipelines

Location of R&D institution headquarters: Mainland China

Ranking of R&D tracks in mainland China: Top 10 Mainland China

Secondary screening: Deals: No

New drug pipeline

trend analysis

distribution statistics

New drug due diligence

A total of 5,912 pieces of data

Only view IST+key clinical IIT studies

Insight Data Monitor (IDM)

Custom S

Drug Ingredient

Recombinant Erythropoiesis Stimulating Protein-NuPIAO

Anmu Qi monoclonal antibody

Libeivitug

Botulinum Toxin Type A-HU-014

Panitumumab N01

The R&D track in mainland China first name: 5

Belonging track: Targets IL17A | Ingredient Classification: Monospecific antibody

ranking

Drug Ingredient

Highest status in Mainland China

Highest Status Time

R&D Enterprise

1st

Secukinumab

Approval

2019-03-28

Novartis

2nd

Ixekizumab

Approval

2019-08-29

Eli Lilly

3rd

xeligekimab

Approval

2024-08-20

Chongqing GenrixBio Biopharmaceutical Co., Ltd.

3rd

Vunakizumab

Approval

2024-08-20

Jiangsu Hengrui Pharmaceuticals

4th

Anmu Qi monoclonal antibody

Approval

2026-02-10

3s guojian Pharmaceutical

View all track rankings

Ranking of tracks in mainland China

7 / total of

4 / total of

1 / total of

7 / total of

Comparison of trial results

Gastric cancer

Biomarkers such as HER2 positivity

Lines of therapy

Trial / Protocol ID

NCT03329690

NCT03556345

Pivotal Clinical Results

Gastric cancer

Group

mOS

ORR

DCR

mDoR (confirmed)

Trastuzumab deruxtecan

12.5 m

42.0%

85.7%

12.5 m

The plan chosen by the re...

8.9 m

12.5%

62.5%

3.9 m

Source: 2022 ASCO GI, 2020 ESMO, pubmed · 2020-05-29

3 Post News

Approvals

US

EMA

JP

Gastric cancer

Group

ORR

mPFS

mOS

Disitamab vedotin

18.1%

4.1 m

7.9 m

Source: pubmed, 2020 ASCO · 2020-05-29

2 Post News

Approvals

CN


Compare clinical results

01. Analyze Global and China Pipeline Competition in Targeted Sectors and Identify BD Opportunities

Uncover Market Opportunities

Gain insights into unmet clinical needs and identify high-potential pipelines in specific segments.

The Disease Competition module visually presents the competitive landscape, clinical efficacy, epidemiology, and clinical guidelines for segmented patient populations such as those defined by biomarkers or disease stages, using racehorse charts, bubble charts, tables, and other intuitive formats. This makes it easy to analyze unmet clinical demands and pinpoint high-potential pipeline projects within refined patient segments.




02. Track New Drug R&D Progress in China and Globally to Enable Efficient Decision-Making

Track Dynamics

Visually analyze the competitive landscape for specific indications / targets within China and globally.

The Global Pipelines module provides visual analytical charts and comprehensive filters to swiftly grasp industry trends, analyze competitive landscape, and identify promising sectors in the Chinese and global market.




02. Track New Drug R&D Progress in China and Globally to Enable Efficient Decision-Making

Forecast Precisely

Accurately predict regulatory review timelines and project competitor approval time for listing.

The Drug Registration Progress module aggregates submission data from the CDE and utilizes a predictive model built on historical approval big data to estimate review duration. This enables thorough tracking of key competitors' regulatory progress in China and provides reliable forecasts of approval time for listing.



Core Strengths



Calibrated Data

100% Authentic and Traceable

Nearly 100,000 global new drug records can be traced back to original sites to ensure data accuracy and to facilitate double check of data.

Credible Data Sources

Covering 30,000+ credible data sources from regulatory agencies both in China and globally, corporate websites, conferences, and other channels, ensuring accurate sources and stable updates.

Professional Analyst Team

Full-time analyst team with backgrounds in Registration / R&D / Project Initiation / Information Research in pharmaceutical enterprises, utilizing manual verification to ensure accuracy.



Easy-to-Use Functionality

600+ Filtering Options and Visualization Analysis

For diverse needs, providing 600+ industry-leading filtering options, as well as visualization charts, online analysis functions, to meet the needs of data retrieval and analysis in different work scenarios.

Abundant Pioneering & Unique Functions

The Timeline function, combined with unique functions such as New Drug/Generic Drug Labels, Combination Therapy, and Clinical Result Visualization, helping quickly obtain key information.



Professional Delivery

Fast Response and Timely Feedback

Dedicated project manager providing one-on-one support backed by an efficient internal mechanism to ensure quick response.

Professional Background and A Shared Professional Language

Professional background ensuring deep understanding of usage scenarios, and deep comprehension of users' needs.

Comprehensive Value-added Services

Providing additional free services such as data retrieval, online lectures, drug review reports and new feature notifications to help users make decisions more precisely and work more efficiently.

Abundant Service Experience

Serving 3000+ clients with extensive and reliable collaboration experience, established partnerships with 92% of RDPAC member companies and 70% of the top 100 pharmaceutical manufacturers.

Get A Quote



db@dxy.cn

Stay Connected



Request A
Free Trial



Official
LinkedIn